JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
125.85
-0.09 (-0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close125.94
Open125.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range125.12 - 126.14
52 Week Range118.62 - 148.32
Volume5,862,442
Avg. Volume6,560,603
Market Cap337.549B
Beta0.54
PE Ratio (TTM)278.43
EPS (TTM)0.45
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.86%)
Ex-Dividend Date2018-05-25
1y Target Est143.20
Trade prices are not sourced from all markets
  • Analysts’ Estimates and Recommendations for Allergan on July 19
    Market Realist2 days ago

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.

  • 3 Stocks That Could Be Added to the Dow Next
    Motley Fool2 days ago

    3 Stocks That Could Be Added to the Dow Next

    There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks2 days ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress
    Zacks2 days ago

    Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress

    The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.

  • TheStreet.com2 days ago

    Three Key Takeaways From Healthcare Earnings Season

    As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.

  • Reuters2 days ago

    Women who sued Johnson & Johnson declare victory after $4.69 billion talc verdict

    A woman who claimed her cancer was caused by using Johnson & Johnson's (JNJ.N) baby powder for decades said she believes justice was served after a jury found the company should pay her and 21 other women $4.69 billion in damages. A St. Louis jury on July 12 concluded that J&J's talc-based products contained asbestos, causing the 22 women, six of whom have died, to develop ovarian cancer. J&J Chief Executive Alex Gorsky earlier this week expressed confidence that the jury decision will be overturned on appeal.

  • Johnson & Johnson and General Motors: Growth and Income Stocks
    Zacks2 days ago

    Johnson & Johnson and General Motors: Growth and Income Stocks

    This week I discuss two companies within the Income Investor portfolio; Johnson & Johnson (JNJ) and General Motors (GM).

  • Reuters2 days ago

    Women who sued J&J declare victory after $4.69 bln talc verdict

    A woman who claimed her cancer was caused by using Johnson & Johnson's baby powder for decades said she believes justice was served after a jury found the company should pay her and 21 other women $4.69 billion in damages. A St. Louis jury on July 12 concluded that J&J's talc-based products contained asbestos, causing the 22 women, six of whom have died, to develop ovarian cancer. J&J Chief Executive Alex Gorsky earlier this week expressed confidence that the jury decision will be overturned on appeal.

  • Motley Fool3 days ago

    These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories

    UnitedHealth delivered an earnings beat, but its shares fell. Johnson & Johnson's stock took a strong jump on earnings, despite recent bad news from a jury.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of JNJ earnings conference call or presentation 17-Jul-18 12:30pm GMT

    Q2 2018 Johnson & Johnson Earnings Call

  • MarketWatch3 days ago

    AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'

    AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.

  • Motley Fool3 days ago

    Should Investors Be Worried About Netflix, United Health, or Johnson & Johnson?

    Wall Street's just dinged two of them and rewarded the third -- but Motley Fool analysts take a longer view.

  • ACCESSWIRE3 days ago

    Free Research Report as Johnson & Johnson's Quarterly Earnings Advanced 14.75%

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.

  • InvestorPlace3 days ago

    New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock

    Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.

  • J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
    Zacks3 days ago

    J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

    The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

  • Healthcare ETFs in Focus Following JNJ Q2 Results
    Zacks4 days ago

    Healthcare ETFs in Focus Following JNJ Q2 Results

    Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.

  • Penn, Johnson & Johnson team up to accelerate innovation
    American City Business Journals4 days ago

    Penn, Johnson & Johnson team up to accelerate innovation

    The university and health care giant are creating a life sciences network hub called JPOD@Philadelphia at the Pennovation Center.

  • Stock Market News For Jul 18, 2018
    Zacks4 days ago

    Stock Market News For Jul 18, 2018

    Markets closed sharply higher on Tuesday, led by a rally in tech stocks.

  • 4 days ago

    Rewind: Why Jim Cramer Is Bullish on Johnson & Johnson Shares

    TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.

  • Benzinga4 days ago

    Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...

  • ACCESSWIRE4 days ago

    Today's Research Reports on Stocks to Watch: Johnson & Johnson and Avid Bioservices

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.

  • See what the IHS Markit Score report has to say about Johnson & Johnson.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. Over the last one-month, outflows of investor capital in ETFs holding JNJ totaled $1.74 billion.

  • J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
    Zacks4 days ago

    J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Asian stocks rise as solid US performance lifts spirits
    Associated Press4 days ago

    Asian stocks rise as solid US performance lifts spirits

    SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.

  • The Wall Street Journal4 days ago

    [$$] Johnson & Johnson’s Pharma Business Fuels Sales Growth

    Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle. Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment. J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates.